Research & Development

In the critical weeks required for a traditional tissue biopsy to navigate the laboratory backlogs of sub-Saharan clinics, a pediatric tumor can expand with such terrifying speed that it effectively outpaces the possibility of survival. While children in high-income nations benefit from survival

While Chimeric Antigen Receptor (CAR) T-cell therapy has successfully transformed the clinical outlook for patients with liquid cancers, its efficacy against solid tumors remains one of the most significant hurdles in modern oncology. Unlike the accessible environment of the bloodstream, where

The pharmaceutical landscape is currently witnessing a high-stakes confrontation as Shanghai Henlius Biotech maneuvers to intercept Pfizer’s dominance in the next generation of lung cancer therapy. At the heart of this struggle is the development of antibody-drug conjugates (ADCs) targeting PD-L1,

Recent breakthroughs in cancer immunology have finally cracked the code on why the body’s most potent defenders often surrender just when the fight against a tumor becomes most critical. For decades, researchers viewed T cell exhaustion as a simple state of fatigue or a loss of energy resulting

The global pharmaceutical landscape is currently navigating a period of intense pressure as the rise of multi-drug resistant pathogens outpaces the traditional speed of antibiotic development. For decades, the process of vetting new chemical entities has been a fragmented journey, requiring

The relentless pursuit of highly effective oncological interventions has historically been hampered by the inability of traditional pharmaceutical agents to distinguish accurately between malignant cells and healthy physiological structures. While chemotherapy and systemic radiation have saved